Evolus, Inc. (EOLS) stock
Close on Nov 12, 2026Market cap $474.24MP/E –Yield –
Evolus, Inc. grew revenue 13.9% to $325.47M over the twelve months to Sep 30, 2026. Free cash flow was -$4.91M. At the latest close the market valued the company at $474.24M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $474.24M
- P/E ratio
- –
- Price to sales
- 1.46
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1.04%
Fundamentals
- Revenue
- $325.47M
- Net income
- -$31.11M
- EPS, diluted
- -$0.47
- Free cash flow
- -$4.91M
- Book value per share
- -$0.57
- Diluted shares
- 66M
Trading
- Next earnings
- Mar 2, 2027 (estimated, during market hours)
- Previous close
- $7.42
- Open
- $7.38
- Day's range
- $7.15 – $7.65
- Volume
- 737,093
- Average volume (20 days)
- 1,089,772
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.14
- 52-week range
- $3.86 – $9.31
- RSI (14 days)
- 51.3
- Volatility (1 year)
- 67.2%
- Relative volume
- 1.38×
- WACC
- 10.0%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | EOLS | S&P 500 | Difference | EOLS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.4% | -2.7% | −4.7 pts | ||
| 3 months | -11.6% | -1.7% | −9.8 pts | ||
| Year to date | +8.0% | +11.9% | −3.9 pts | ||
| 1 year | -1.6% | +12.0% | −13.6 pts | ||
| 3 years | -10.3% | +78.2% | −88.4 pts | -3.5% | +21.2% |
| 5 years | -0.6% | +73.2% | −73.8 pts | -0.1% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Evolus filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
About Evolus
Pharmaceutical Preparations
The company operates in the medical aesthetics industry, developing and marketing non-reimbursed, cash-pay aesthetic products. Its primary offerings comprise injectable neurotoxins and hyaluronic acid dermal fillers designed to treat facial lines and folds. Specifically, it commercializes Jeuveau, an injectable botulinum toxin type A formulation for frown lines, and the Evolysse collection of hyaluronic acid gels for facial wrinkles and volume restoration. The company sells these treatments directly to licensed aesthetic practitioners who administer them to adult consumers.
Company profile, executives and historyEvolus stock: common questions
What is Evolus's stock price?
EOLS closed at $7.18 on Nov 12, 2026, down 3.23% on the day. Over the past 52 weeks it traded between $3.86 and $9.31.
What is Evolus's market cap?
Evolus was worth $474.24M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is EOLS's P/E ratio?
Evolus lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.47), so it has no meaningful P/E ratio.
How much revenue does Evolus make?
Evolus reported revenue of $325.47M for the twelve months to Sep 30, 2026, up 13.9% from a year earlier.
Does Evolus pay a dividend?
No. Evolus has not paid a cash dividend over the last twelve months.
When does Evolus report earnings next?
Evolus is expected to report Q4 FY2026 results on Mar 2, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has EOLS stock performed over the past year?
Including dividends, EOLS returned -1.6% over the past year, against +12.0% for the S&P 500.
How many EOLS shares are sold short?
6M shares were sold short at the latest FINRA report, 9.51% of the float, or 9.4 days of average trading volume.
Who are Evolus's competitors?
Companies most similar to Evolus by business, industry and size include ARQT, RIGL, ORGO, HROW, AUPH.
See a number that looks wrong?